Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03314935 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 149
- Enrollment target
- 10
- Study locations
NCT03314935 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 149 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT03314935, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 149 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG 5-Fluorouracil
- DRUG INCB001158
Study Locations (10)
Other
- Grand Hopital de Charleroi - Department of Medical Oncology - Brussels
- Institut Jules Bordet - Clinical Trials Conduct Unit - Brussels
- UCL Cancer Institute - London
- The Christie NHS Foundation Trust - Manchester
Alabama
- University of Alabama - Birmingham
- USA Mitchell Cancer Center - Mobile
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
California
- UC Davis - Comprehensive Cancer Centre - Sacramento
Georgia
- Northwest Georgia Oncology Centers - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03314935
The ClinicalTrials.gov registry entry for NCT03314935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Leucovorin is the first listed.
NCT03314935 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, Alabama, Texas.
Frequently Asked Questions
What is clinical trial NCT03314935 about?
NCT03314935 is a clinical study titled "A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors". The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
What is the current status of trial NCT03314935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 149 participants. The study started on 2017-11-21. Estimated completion is 2022-11-28.
What conditions does trial NCT03314935 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Solid Tumors, Colorectal Cancer (CRC), Biliary Tract Cancer (BTC).
What interventions are being tested in trial NCT03314935?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG), 5-Fluorouracil (DRUG), INCB001158 (DRUG).
Who is sponsoring clinical trial NCT03314935?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03314935 being conducted?
This trial has 10 study locations across Alabama, California, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.